|
KMID : 0371320130850040154
|
|
Journal of the Korean Surgical Society
2013 Volume.85 No. 4 p.154 ~ p.160
|
|
|
Prospective multicenter phase II clinical trial of FOLFIRI chemotherapy as a neoadjuvant treatment for colorectal cancer with multiple liver metastases
|
|
Kim Ji-Yeon
Kim Jin-Soo
Baek Moo-Jun
Kim Chang-Nam
Choi Won-Jun
Park Dong-Kook
Namgung Hwan
Lee Sang-Chul
Lee Sang-Jeon
|
|
|
Abstract
|
|
|
|
Purpose: This study evaluated the efficacy of neoadjuvant chemotherapy combining 5-flurouracil/folinic acid with irinotecan (FOLFIRI) in colorectal multiple liver metastases regardless of resectability. Methods: Forty-four patients with multiple (at least two) colorectal liver metastases were enrolled at seven tertiary referral hospitals between May 2007 and September 2010. All patients received the FOLFIRI chemotherapeutic regimen. Response to chemotherapy was assessed after three cycles (6 weeks) and once more after six cycles (12 weeks) of treatment. Results: Objective response was noted in 27 patients (61.4%) and 4 patients (9.1%) had progressive disease. Of 44 patients, 10 patients (22.7%) underwent curative surgery (R0 resection) and 34 patients did not receive R0 resection. Grades 3 to 4 hematological toxicity was noted in 12 patients (27.3%) and grades 3 to 4 nonhematologic toxicity was identified in 5 patients (11.4%). Conclusion: FOLFIRI chemotherapy as a neoadjuvant chemotherapy for multiple colorectal liver metastases regardless of resectability demonstrated the possibility of R0 resection, high rate of objective response, and tolerable toxicities in this study.
|
|
|
KEYWORD
|
|
|
Colorectal cancer, Neoadjuvant therapy, Metastasis, Chemotherapy
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|